Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (9149)	3/12/1999 4:53:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

From the 10K "The Company is also considering adapting the facility to expand production of its NEUPREX(R) product. This adaptation, if pursued, is estimated to cost significantly less than a new facility. The Company's current estimate of net cash flows from NEUPREX(R) that would be manufactured in the facility exceeds the current carrying value of the facility plus anticipated costs to renovate it for NEUPREX(R) production. If the Company pursues this alternative, the actual net cash flows that the Company will ultimately realize as well as the estimated costs to renovate the facility could differ materially from the estimated amounts."

To: Robert K. who wrote (9149)	3/12/1999 6:20:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

I trust Wisconsin. When mortality measured by severity, results did not change. Also if resistance is in any way a concer on might postulate that fewer non survivors might exist as time moves on. (my idea not that of the real dudes that wrote the article). Pediatr Infect Dis J 1989 Jan;8(1):8-11 Trends in mortality in children hospitalized with meningococcal infections, 1957 to 1987. Havens PL, Garland JS, Brook MM, Dewitz BA, Stremski ES, Troshynski TJ Department of Pediatrics, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee 53201. We reviewed charts of 261 children seen at Children's Hospital of Wisconsin from 1957 to 1987 with culture-proven meningococcemia or meningococcal meningitis, and we analyzed trends in mortality and disease severity for that interval. Overall case fatality was 10%, ranging from 9% in the period 1957 to 1963, to 16% in the period 1980 to 1987 (P = 0.15). The percent of patients admitted with severe disease increased from 14% to 38% (P = 0.001). When stratified by disease severity, case-fatality rates did not change with time. We conclude that technologic advances of the past 30 years had no measurable impact on mortality from meningococcal infection in our hospital and that crude case-fatality rates can be misleading if disease severity is not considered. MeSH Terms: Me again, so over 30 years there was no change in the survival rates in Wisconsin, a great state, with some of the cleanest hospitals that exist anywhere, but in the u.k. from 1997 to 1998 there was this big increase in survivorship! Give me a break! Did the regular posters not survive some event, called Friday? Or the release of the S3. did I alone survive some clinical trial that will never end because of a pre established target that was too high?